Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 304.86% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Friday, December 13th. StockNews.com upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, December 16th. Finally, Barclays raised their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Sangamo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Sangamo Therapeutics Stock Up 6.9 %

Shares of SGMO opened at $2.47 on Thursday. The company has a market capitalization of $515.36 million, a price-to-earnings ratio of -3.29 and a beta of 1.15. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The stock’s 50-day moving average price is $1.94 and its 200-day moving average price is $1.12.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same period in the previous year, the company posted ($0.34) earnings per share. As a group, equities analysts anticipate that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Several institutional investors have recently modified their holdings of the stock. Meritage Portfolio Management raised its position in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,740 shares during the last quarter. XTX Topco Ltd increased its stake in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 64,981 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 38,850 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Sangamo Therapeutics in the third quarter valued at approximately $150,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $67,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.